IGF-1 LR3 vs TB-500: What Is the Difference?
One is a folded protein that will fall apart if you look at it wrong. The other is a floppy chain that shrugs off almost everything. Same research area, opposite temperaments.
In plain English
IGF-1 LR3 is a modified version of insulin-like growth factor 1, a natural growth-signalling protein. Two changes were made to it so that it stays free in solution instead of being grabbed and held by carrier proteins.
TB-500 is a synthetic piece of Thymosin Beta-4, a protein present in nearly every cell and concentrated in wound fluid, studied for its role in cell movement.
The difference, without the jargon
The everyday difference is fragility. IGF-1 LR3 is a real protein with a folded three-dimensional shape held together by internal bonds — and a folded protein can come undone. Once it does, it cannot refold itself, and crucially it will still look perfectly fine and weigh exactly the same. This is why a meaningful lab report for it includes a functional test rather than only a purity number: chemical purity cannot tell you whether the shape survived. It also will not dissolve properly in plain water, needing a mildly acidic liquid first. TB-500 has no folded shape to lose and dissolves in ordinary bacteriostatic water without ceremony. If you carry habits from short peptides over to a folded protein, this is the pair that shows you why that fails.
Common questions
What is the difference between IGF-1 LR3 and TB-500?
IGF-1 LR3 is a folded protein — a modified growth factor — that is fragile and needs acidic liquid to dissolve. TB-500 is a short unfolded chain that dissolves easily in ordinary bacteriostatic water. They are studied in different aspects of tissue and growth research.
Why can't IGF-1 LR3 just be mixed with water?
It does not dissolve well at neutral acidity. The standard approach is to dissolve it first in a small amount of dilute acetic acid or dilute hydrochloric acid, then dilute into whatever buffer the work requires. Adding plain water often leaves visible undissolved material — that is expected chemistry, not a faulty vial.
What does "LR3" mean?
It is shorthand for two modifications: "Long" refers to an extra stretch of amino acids added to one end, and "R3" to an arginine swapped in at position three. The arginine change is the important one — it stops carrier proteins from binding and holding the molecule.
Why do lab reports for IGF-1 LR3 include an activity test?
Because purity does not prove the protein is folded correctly. A misfolded protein has exactly the same weight and can look clean on standard tests while being functionally inert. Only a test of what it actually does can tell the two apart.
Technical reference below
How they actually differ
Comparing the two: IGF-1 LR3 is recombinant 83-residue protein analogue of igf-1, while TB-500 (Thymosin Beta-4) is synthetic fragment of thymosin beta-4 — different molecular classes with different handling consequences; they call for different primary diluents (dilute acetic acid (0.1 m) or 10 mm hcl — required for initial dissolution versus bacteriostatic water (0.9% benzyl alcohol)); their leading degradation routes differ (denaturation and aggregation for IGF-1 LR3, methionine sulfoxide formation for TB-500 (Thymosin Beta-4)), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
IGF-1 LR3 — origin
IGF-1 LR3 is an engineered analogue carrying two changes to native IGF-1: an arginine substitution at position 3 and a 13-residue N-terminal extension. The Arg3 substitution is the functional one — it drastically reduces binding to IGF binding proteins, which normally sequester the great majority of circulating IGF-1. The result is a molecule that stays free rather than bound.
TB-500 (Thymosin Beta-4) — origin
TB-500 corresponds to the active region of Thymosin Beta-4, a 43-residue actin-sequestering protein present in virtually every mammalian cell type and abundant in wound fluid and platelets. Research interest followed the observation that the protein's activity in tissue-organisation models is largely retained by a short fragment of it.
IGF-1 LR3 research themes
The Arg3 substitution reduces binding-protein affinity, which is the entire design rationale.
Widely used in cell-culture research as a growth-factor supplement.
Studied in muscle-biology research models.
The canonical downstream pathway examined in IGF-1 receptor research.
TB-500 (Thymosin Beta-4) research themes
The defining studied mechanism: binding G-actin and influencing the polymerisation equilibrium that governs cell motility.
Investigated in models where directed cell movement into a tissue defect is the measured endpoint.
Two of the better-populated preclinical literatures for the parent protein.
Studied for effects on inflammatory signalling in tissue-injury models.
IGF-1 LR3 handling
- Dissolve in dilute acetic acid or dilute HCl FIRST; do not attempt direct dissolution in water or PBS.
- Add carrier protein (e.g. 0.1% BSA) for storage of dilute solutions to prevent adsorptive loss.
- Prepare single-use aliquots — freeze–thaw denaturation is irreversible.
- Do not vortex; agitation denatures folded proteins at the air–liquid interface.
TB-500 (Thymosin Beta-4) handling
- Minimise headspace exposure — each opening introduces oxygen that drives methionine oxidation.
- Keep reconstituted vials out of direct light, including bench lighting over long sessions.
- Introduce diluent against the vial wall; the cake is light and can be dispersed by a direct stream before it dissolves.
Both third-party tested
Every Popular Peptides batch of IGF-1 LR3 and TB-500 (Thymosin Beta-4) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
IGF-1 LR3 reference
Related comparisons
IGF-1 LR3 and TB-500 (Thymosin Beta-4) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.